Ebola Outbreak in DR Congo Passes 11,300 Cases as Two Vaccines Move to Phase 2 Trials

The Library Media — National & World · World Desk

By Maya Wilson, World Desk Lead, The Library Media

Share

Published November 17, 2026 · 1:23 PM PT

The Ebola outbreak in the Democratic Republic of the Congo has surpassed 11,300 cases and 5,500 deaths, with between 400 and 500 new infections still being reported each week, World Health Organization Director-General Tedros Adhanom Ghebreyesus said Tuesday.

The outbreak is caused by the Bundibugyo Ebola virus. The figures were reported by Tedros at a WHO news conference in Geneva on November 17. UN News also reported that the epidemic had more than doubled in three months, with cases recorded in 67 health zones across eight provinces.

Tedros warned that insecurity, attacks on health workers and delays in identifying infections continued to undermine efforts to contain the outbreak. He said attacks on health workers also discouraged people from seeking care at Ebola treatment centers, adding to the difficulties facing efforts to limit transmission.

The outbreak’s continuing scale comes as two experimental vaccines developed specifically against the Bundibugyo virus prepare to enter phase 2 clinical trials in the DRC. The candidates are expected to begin testing next week, with the first trial activity anticipated in the eastern city of Bunia.

One vaccine, ChAdOx1, was developed by Oxford University and the Serum Institute of India. The second candidate was developed by Moderna.

Dr. Meg Doherty of the WHO said the two candidates received approval last week to advance to phase 2 of the Tumani randomized controlled trial. Testing is expected to begin on November 26 or 27 in Bunia.

The next phase will assess the vaccines’ safety and immunogenicity, meaning their ability to trigger an immune response. Candidates that meet the required criteria will advance to phase 3, when researchers will evaluate their effectiveness against a comparator.

The Tumani trial launched on October 23 and was designed to accommodate additional vaccine candidates as they become available. More than 140 participants have already enrolled, Doherty said. Thousands are expected to take part as testing expands to additional sites and mobile teams.

The WHO’s reported case and death figures, alongside the continuing weekly infections, underscore the scale of the outbreak as the vaccine candidates enter the next stage of clinical evaluation. The phase 2 trials will first examine safety and immune response; assessment of effectiveness is reserved for phase 3.

Maya Wilson
World Desk Lead, The Library Media

From The Library — the estate of our family.

Follow Us

X Facebook Instagram Threads Mastodon Bluesky

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top